Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOBYVL)

Drug Name
Butyrylthiocholine Drug Info
Synonyms
BUTYRYLTHIOCHOLINE; 4555-00-4; CHEMBL139908; CHEBI:41055; 2-(BUTYRYLSULFANYL)-N,N,N-TRIMETHYLETHANAMINIUM; CHEMBL148530; (Propylcarbonylthioethyl)trimethylammonium iodide; butanoylthiocholine; s-butyrylthiocholine; S-butanoylthiocholine; 2ha7; AC1L2GSR; SCHEMBL570209; Ethanaminium, N,N,N-trimethyl-2-((1-oxobutyl)thio)-; BDBM8978; CTK4I8879; AWBGQVBMGBZGLS-UHFFFAOYSA-; DTXSID00196553; ZINC1592591; MCULE-2436087085; DB04250; 2-butanoylsulfanylethyl(trimethyl)azanium; AN-22197; AJ-27734; CJ-25507
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
20689
ChEBI ID
CHEMBL139908
CAS Number
CAS 4555-00-4
TTD Drug ID
DMOBYVL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Cholinesterase (BCHE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hexafluronium bromide DMFY307 Spasm MB47.3 Approved [2]
MEPTAZINOL DMPSB8F Pain MG30-MG3Z Approved [3]
Eptastigmine DMTV7ZM Cognitive impairment 6D71 Phase 3 [4]
(-)-Phenserine DMNCY1I Alzheimer disease 8A20 Phase 3 [5]
Plasma derived human butyrylcholinesterase DMF3IBC Neurotoxicity NE61 Phase 1 [6]
Protexia DME1Y9W Alzheimer disease 8A20 Phase 1 [7]
JES-9501 DMYR3IE Alzheimer disease 8A20 Phase 1 [8]
Tetra-hydro-isoquinoline derivative 3 DMCZA45 N. A. N. A. Patented [9]
Tetra-hydro-isoquinoline derivative 1 DML86IO N. A. N. A. Patented [9]
Tetra-hydro-isoquinoline derivative 2 DM5CKVF N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholinesterase (BCHE) TTEB0GD CHLE_HUMAN Inhibitor [1]

References

1 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
2 Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
3 Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
4 Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
5 Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
6 Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
7 In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
8 Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
9 A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.